News

Mirdametinib, formerly PD-0325901, is an oral and small molecule inhibitor of MEK1 and MEK2. The company has already secured orphan drug designation from the US Food and Drug

The late-stage study called MONARCH 2 met its secondary endpoint of overall survival for Verzenio in combination with the endocrine therapy fulvestrant. The trial involved 669 patients, who

OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated

In the late-stage trial called KEYNOTE-522, Keytruda and chemotherapy combination achieved pathological complete response (pCR) following the neoadjuvant part of the neoadjuvant/adjuvant study regimen. pCR is defined as

Under an all-stock Reverse Morris Trust transaction, each share of Mylan will be converted into one share of the new company. The deal allows Pfizer shareholders to own

The application also includes data for cabotegravir oral tablets, intended for use as oral lead-in therapy prior to the commencement of injectable therapy. Deborah Waterhouse, CEO of ViiV

AVT02 is a mAb biosimilar to AbbVie’s HUMIRA, which is a leading drug indicated for the treatment of several autoimmune diseases, including (but not limited to) Rheumatoid Arthritis

NeuroSTAT’s FDA Fast Track designation makes NeuroVive eligible, for example, for more frequent meetings and written communication with the FDA, continuous feedback on each section of its New

The committee has recommended the approval of Tecentriq plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of adults with metastatic non-squamous non-small cell lung